In August 2024, the company opened the research and development hub, Lilly Seaport Innovation Center, in Boston's Seaport district, US. "Eli Lilly to expand US pharma manufacturing with four new ...
16d
Pharmaceutical Technology on MSNEli Lilly to expand US pharma manufacturing with four new sitesEli Lilly has announced plans to expand its domestic medicine production in the US by establishing four new pharmaceutical ...
INDIANAPOLIS - Eli Lilly and Company (NYSE: NYSE:LLY), a global pharmaceutical firm, announced today the inauguration of the Lilly Seaport Innovation Center (LSC) in Boston's... Eli Lilly and ...
TOOsonix Partners with MikronMed to Introduce Innovative Dermatological Therapy in the Nordic Region
TOOsonix A/S, a leader in high-intensity focused ultrasound technology for dermatology, has partnered with MikronMed AB, a top distributor of medical equipment in the ...
AbbVie made a $350 million upfront payment to Gubra for rights to the drug, called GUB014295. Gubra is also eligible to receive another $1.9 billion if certain development and sales milestones are met ...
Seaport emerges with $100 million in funding ... Paul, who was head of R&D at Eli Lilly before moving to take the top job at Karuna to spearhead development of its KarXT schizophrenia therapy ...
INDIANAPOLIS - Eli Lilly and Company (NYSE: NYSE:LLY), a global pharmaceutical firm, announced today the inauguration of the Lilly Seaport Innovation Center (LSC) in Boston's... Eli Lilly and Company ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results